{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:44:50Z","timestamp":1773665090784,"version":"3.50.1"},"reference-count":104,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.cjca.2012.02.007","type":"journal-article","created":{"date-parts":[[2012,4,6]],"date-time":"2012-04-06T08:09:30Z","timestamp":1333699770000},"page":"590-598","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["An \u201cI\u201d on Cardiac Hypertrophic Remodelling: Imidazoline Receptors and Heart Disease"],"prefix":"10.1016","volume":"28","author":[{"given":"Suhayla","family":"Mukaddam-Daher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2012.02.007_bib1","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1172\/JCI31044","article-title":"ECM remodeling in hypertensive heart disease","volume":"117","author":"Berk","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.cjca.2012.02.007_bib2","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.pcad.2009.05.002","article-title":"Clinical impact of left ventricular hypertrophy and implications for regression","volume":"52","author":"Artham","year":"2009","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.cjca.2012.02.007_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/HJH.0b013e328340d787","article-title":"Hypertensive left ventricular hypertrophy risk: beyond adaptive cardiomyocytic hypertrophy","volume":"29","author":"Frohlich","year":"2011","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2012.02.007_bib4","doi-asserted-by":"crossref","first-page":"R26","DOI":"10.1152\/ajpregu.00424.2007","article-title":"The role of local and systemic renin angiotensin system activation in a genetic model of sympathetic hyperactivity-induced heart failure in mice","volume":"294","author":"Ferreira","year":"2008","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1016\/j.cjca.2012.02.007_bib5","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S1734-1140(09)70143-4","article-title":"Chronic beta-adrenergic activation-induced left ventricular systolic dysfunction is associated with systemic release of TNF-alpha and IL-1-beta in rats","volume":"61","author":"Kumar","year":"2009","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.cjca.2012.02.007_bib6","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/j.1476-5381.2010.01043.x","article-title":"Myocardial oxidative stress contributes to transgenic \u03b22-adrenoceptor activation-induced cardiomyopathy and heart failure","volume":"162","author":"Xu","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib7","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00395-006-0635-y","article-title":"Interstitial remodeling in beta1-adrenergic receptor transgenic mice","volume":"102","author":"Seeland","year":"2007","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.cjca.2012.02.007_bib8","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1161\/hc0102.101365","article-title":"Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress","volume":"105","author":"Esposito","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.02.007_bib9","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/46040","article-title":"Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission","volume":"402","author":"Hein","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.cjca.2012.02.007_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1161\/01.HYP.0000226859.42064.ea","article-title":"Survival benefits of different anti-adrenergic interventions in pressure overload left ventricular hypertrophy\/failure","volume":"48","author":"Perlini","year":"2006","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib11","first-page":"S55","article-title":"Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study","volume":"16","author":"Sadowski","year":"1998","journal-title":"J Hypertens Suppl"},{"key":"10.1016\/j.cjca.2012.02.007_bib12","doi-asserted-by":"crossref","first-page":"36A","DOI":"10.1016\/0002-9149(94)90040-X","article-title":"Effects of one-year treatment with rilmenidine on systemic hypertension-induced left ventricular hypertrophy in hypertensive patients","volume":"74","author":"Trimarco","year":"1994","journal-title":"Am J Cardiol"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2012.02.007_bib13","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1097\/00005344-199424001-00008","article-title":"I1-imidazoline-receptor agonists in the treatment of hypertension: an appraisal of clinical experience","volume":"24","author":"Ollivier","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib14","first-page":"61","article-title":"Effect of moxonidine on left ventricular hypertrophy in hypertensive patients","volume":"4","author":"Haczynski","year":"2001","journal-title":"J Clin Basic Cardiol"},{"issue":"suppl 4","key":"10.1016\/j.cjca.2012.02.007_bib15","first-page":"249","article-title":"Double blind, multicentre comparison of moxonidine and enalapril and their effects on blood pressure and left ventricular mass: results of the MOXENA study [abstract P1051]","volume":"20","author":"Schafers","year":"2002","journal-title":"J Hypertens"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2012.02.007_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00004872-199715011-00007","article-title":"The use of moxonidine in the treatment of hypertension","volume":"15","author":"Prichard","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2012.02.007_bib17","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2165\/00003495-200666040-00006","article-title":"Moxonidine: a review of its use in essential hypertension","volume":"66","author":"Fenton","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.cjca.2012.02.007_bib18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199424001-00002","article-title":"Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla","volume":"24","author":"Haxhiu","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib19","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00004872-199715010-00010","article-title":"Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension","volume":"15","author":"K\u00fcppers","year":"1997","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2012.02.007_bib20","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/01.HYP.32.6.1022","article-title":"I1-imidazoline agonist moxonidine decreases sympathetic nerve activity and blood pressure in hypertensives","volume":"32","author":"Wenzel","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib21","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/BF00143521","article-title":"Hemodynamic and neurohumoral effects of moxonidine in patients with essential hypertension","volume":"5","author":"Mitrovic","year":"1991","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.cjca.2012.02.007_bib22","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0167-5273(00)00258-8","article-title":"Anti-arrhythmic properties of moxonidine\u2014implications for the MOXCON study","volume":"74","author":"Wolk","year":"2000","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2012.02.007_bib23","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1161\/01.HYP.35.6.1264","article-title":"Chronic I(1)-imidazoline agonism: sympathetic mechanisms in hypertension","volume":"35","author":"Greenwood","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib24","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1111\/j.1523-1755.2005.09305.x","article-title":"Efficacy of moxonidine in the treatment of hypertension in obese, non-controlled hypertensive patients","volume":"93","author":"Abellan","year":"2005","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2012.02.007_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1111\/j.1368-5031.2006.00951.x","article-title":"Selective imidazoline agonist moxonidine in obese hypertensive patients","volume":"60","author":"Sanjuliani","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.cjca.2012.02.007_bib26","first-page":"41","article-title":"Comparison of the effectiveness of moxonidine and prestarium in postmenopausal women with mild and moderate arterial hypertension [in Russian]","volume":"84","author":"Bakhshaliev","year":"2006","journal-title":"Klin Med (Mosk)"},{"key":"10.1016\/j.cjca.2012.02.007_bib27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.5414\/CPP45394","article-title":"Effects of sympatholytic therapy on insulin sensitivity indices in hypertensive postmenopausal women","volume":"45","author":"Kaaja","year":"2007","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.cjca.2012.02.007_bib28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.clinthera.2007.03.015","article-title":"Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial","volume":"29","author":"Derosa","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.cjca.2012.02.007_bib29","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1177\/147323000803600111","article-title":"Effects of sympatholytic therapy with moxonidine on serum adiponectin levels in hypertensive women","volume":"36","author":"Ebin\u00e7","year":"2008","journal-title":"J Int Med Res"},{"key":"10.1016\/j.cjca.2012.02.007_bib30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1463-1326.2006.00606.x","article-title":"Moxonidine improves glycemic control in mildly hypertensive, overweight patients: a comparison with metformin","volume":"8","author":"Chazova","year":"2006","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.cjca.2012.02.007_bib31","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1097\/HJH.0b013e328311cf37","article-title":"Central sympatholytic therapy has anti-inflammatory properties in hypertensive postmenopausal women","volume":"26","author":"Poyhonen-Alho","year":"2008","journal-title":"J Hypertens"},{"key":"10.1016\/j.cjca.2012.02.007_bib32","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/00041552-200209000-00004","article-title":"Recent developments in the treatment of obesity-related hypertension","volume":"11","author":"Pischon","year":"2002","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.cjca.2012.02.007_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/j.1365-2125.2003.02058.x","article-title":"The I1-imidazoline agonist moxonidine decreases sympathetic tone under physical and mental stress","volume":"57","author":"Wenzel","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib34","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1097\/01.ASN.0000143471.10750.8C","article-title":"Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure","volume":"15","author":"Neumann","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2012.02.007_bib35","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2710.2005.00672.x","article-title":"Use of moxonidine in elderly patients with resistant hypertension","volume":"30","author":"Martin","year":"2005","journal-title":"J Clin Pharm Ther"},{"key":"10.1016\/j.cjca.2012.02.007_bib36","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1097\/HJH.0b013e32833c2100","article-title":"Effects of moxonidine on sympathetic nerve activity in patients with end-stage renal disease","volume":"28","author":"Hausberg","year":"2010","journal-title":"J Hypertens"},{"issue":"suppl 1","key":"10.1016\/j.cjca.2012.02.007_bib37","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1097\/00005344-199424001-00005","article-title":"Moxonidine and hydrochlorothiazide in combination: a synergistic antihypertensive effect","volume":"24","author":"Frei","year":"1994","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib38","first-page":"541","article-title":"The efficacy and safety of moxonidine in patients with metabolic syndrome (the O.B.E.Z.I.T.A. trial) [in Czech]","volume":"57","author":"Krupicka","year":"2011","journal-title":"Vnitr Lek"},{"key":"10.1016\/j.cjca.2012.02.007_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.neuropharm.2009.06.035","article-title":"Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine","volume":"57","author":"Taksande","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.cjca.2012.02.007_bib40","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/ajh\/5.2.76","article-title":"Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats","volume":"5","author":"Amann","year":"1992","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.cjca.2012.02.007_bib41","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1111\/j.1476-5381.2011.01355.x","article-title":"Improved cardiac structure and performance by moxonidine in SHR involve inhibition of cytokines, p38 MAPK, and Akt","volume":"164","author":"Aceros","year":"2011","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib42","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/sj.bjp.0707588","article-title":"Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation","volume":"153","author":"Paquette","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib43","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1517\/14728222.10.2.239","article-title":"Natriuretic peptides as therapeutic targets","volume":"10","author":"Mukaddam-Daher","year":"2006","journal-title":"Exp Opin Therap Targets"},{"key":"10.1016\/j.cjca.2012.02.007_bib44","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1196\/annals.1304.030","article-title":"Cardiac effects of moxonidine in spontaneously hypertensive obese rats","volume":"1009","author":"Mukaddam-Daher","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cjca.2012.02.007_bib45","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1196\/annals.1304.035","article-title":"Normalization of up-regulated cardiac imidazoline I(1)-receptors and natriuretic peptides by chronic treatment with moxonidine in spontaneously hypertensive rats","volume":"1009","author":"El-Ayoubi","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cjca.2012.02.007_bib46","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1161\/HYPERTENSIONAHA.108.126524","article-title":"Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in Stroke Prone Spontaneous Hypertensive Rats","volume":"53","author":"Mukaddam-Daher","year":"2009","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib47","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1161\/01.CIR.97.14.1382","article-title":"Pathophysiologically relevant concentrations of tumor necrosis factor-\u03b1 promote progressive left ventricular dysfunction and remodeling in rats","volume":"97","author":"Bozkurt","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.02.007_bib48","doi-asserted-by":"crossref","first-page":"3524","DOI":"10.1152\/ajpheart.00919.2007","article-title":"p38 and ERK1\/2 MAPKs mediate the interplay of TNF-alpha and IL-10 in regulating oxidative stress and cardiac myocyte apoptosis","volume":"293","author":"Dhingra","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.cjca.2012.02.007_bib49","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1161\/HYPERTENSIONAHA.109.148635","article-title":"Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats","volume":"56","author":"Melendez","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1161\/hy0202.103268","article-title":"Stimulation of collagen production by transforming growth factor-\u03b21 during differentiation of cardiac fibroblasts to myofibroblasts","volume":"39","author":"Petrov","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib51","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1161\/CIRCRESAHA.109.213199","article-title":"MAPK-activated protein kinase-2 in cardiac hypertrophy and cyclooxygenase-2 regulation in heart","volume":"106","author":"Streicher","year":"2010","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2012.02.007_bib52","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2004.06.029","article-title":"Activation of adenosine receptors inhibits tumor necrosis factor-alpha release by decreasing TNF-alpha mRNA stability and p38 activity","volume":"497","author":"Fotheringham","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib53","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nrm1983","article-title":"Regulation of cardiac hypertrophy by intracellular signalling pathways","volume":"7","author":"Heineke","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.cjca.2012.02.007_bib54","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1161\/01.CIR.101.6.660","article-title":"Akt promotes survival of cardiomyocytes in vitro and protects against ischemia reperfusion injury in mouse heart","volume":"101","author":"Fujio","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.02.007_bib55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.yjmcc.2004.12.002","article-title":"Akt3 overexpression in the heart results in progression from adaptive to maladaptive hypertrophy","volume":"38","author":"Taniyama","year":"2005","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.cjca.2012.02.007_bib56","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2010.05.086","article-title":"Integrin-linked kinase is a central mediator in angiotensin II type 1- and chemokine receptor CXCR4 signaling in myocardial hypertrophy","volume":"397","author":"Bettink","year":"2010","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cjca.2012.02.007_bib57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/hy0202.102699","article-title":"Integrins play a critical role in mechanical stress-induced p38-MAPK activation","volume":"39","author":"Aikawa","year":"2002","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib58","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1161\/01.HYP.0000258703.36986.13","article-title":"Beta-1 integrins modulate beta-adrenergic receptor\u2013stimulated cardiac myocytes apoptosis and myocardial remodeling","volume":"49","author":"Krishnamurthy","year":"2007","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib59","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.cardiores.2003.09.026","article-title":"Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts","volume":"61","author":"Van Kerckhoven","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2012.02.007_bib60","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.lfs.2011.01.008","article-title":"Functional and molecular effects of imidazoline receptor activation in heart failure","volume":"88","author":"Stabile","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.cjca.2012.02.007_bib61","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0167-5273(00)00319-3","article-title":"The effects of chronic, sustained-release moxonidine therapy on clinical and neurohumoral status in patients with heart failure","volume":"75","author":"Dickstein","year":"2000","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2012.02.007_bib62","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1161\/01.CIR.0000014212.04920.62","article-title":"Effects of sustained-release moxonidine, an imidazoline agonist, on plasma norepinephrine in patients with chronic heart failure","volume":"105","author":"Swedberg","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.02.007_bib63","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0167-5273(99)00120-5","article-title":"Heart Failure 99\u2013the MOXCON story","volume":"71","author":"Coats","year":"1999","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.cjca.2012.02.007_bib64","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1388-9842(03)00163-6","article-title":"Adverse mortality effect of central sympathetic inhibition with sustained-release moxonidine in patients with heart failure (MOXCON)","volume":"5","author":"Cohn","year":"2003","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cjca.2012.02.007_bib65","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1161\/01.CIR.0000013788.71817.16","article-title":"The \u201cunsympathetic\u201d nervous system of heart failure","volume":"105","author":"Floras","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.02.007_bib66","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1042\/CS20050037","article-title":"Influence of central inhibition of sympathetic nervous activity on myocardial metabolism in chronic heart failure: acute effects of the imidazoline I1-receptor agonist moxonidine","volume":"110","author":"Mobini","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.cjca.2012.02.007_bib67","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1749-6632.1999.tb09367.x","article-title":"Mechanism of the sympatho-inhibition produced by the clonidine-like drugs rilmenidine and moxonidine","volume":"881","author":"Szabo","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cjca.2012.02.007_bib68","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1124\/jpet.102.044966","article-title":"Modification of noradrenaline release in pithed spontaneously hypertensive rats by I1-binding sites in addition to alpha2-adrenoceptors","volume":"304","author":"Raasch","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cjca.2012.02.007_bib69","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0022-3565(25)21405-7","article-title":"Central cardiovascular effects of alpha-adrenergic drugs: differences between catecholamines and imidazolines","volume":"230","author":"Bousquet","year":"1984","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cjca.2012.02.007_bib70","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1749-6632.1999.tb09339.x","article-title":"The I1-imidazoline receptor and its cellular signalling pathways","volume":"881","author":"Ernsberger","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cjca.2012.02.007_bib71","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0006-8993(96)01372-8","article-title":"Activation of phosphatidylcholine-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla","volume":"749","author":"Separovic","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.cjca.2012.02.007_bib72","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0014-2999(01)00834-2","article-title":"Imidazoline I receptor-induced activation of 1 phosphatidylcholine-specific phospholipase C elicits mitogen-activated protein kinase phosphorylation in PC12 cells","volume":"415","author":"Zhang","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib73","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1046\/j.1471-4159.2001.00632.x","article-title":"The I1-imidazoline receptor in PC12 pheochromocytoma cells activates protein kinases C, extracellular signal-regulated kinase (ERK) and c-jun N-terminal kinase (JNK)","volume":"79","author":"Edwards","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.cjca.2012.02.007_bib74","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/S0026-895X(24)23223-5","article-title":"Coupling of I(1) imidazoline receptors to the cAMP pathway: studies with a highly selective ligand, benazoline","volume":"57","author":"Greney","year":"2000","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib75","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.bbrc.2011.05.058","article-title":"Modulation of N-type Ca2+ currents by moxonidine via imidazoline I1 receptor activation in rat superior cervical ganglion neurons","volume":"409","author":"Kim","year":"2011","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.cjca.2012.02.007_bib76","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1124\/jpet.107.129049","article-title":"Inhibition of nischarin expression attenuates rilmenidine-evoked hypotension and phosphorylated extracellular signal-regulated kinase 1\/2 production in the rostral ventrolateral medulla of rats","volume":"324","author":"Zhang","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cjca.2012.02.007_bib77","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/01.fjc.0000211794.68152.04","article-title":"Antihypertensive responses elicited by central moxonidine in rats: possible role of nitric oxide","volume":"47","author":"Moreira","year":"2006","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib78","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/cvr\/cvp202","article-title":"Sympathoinhibitory mechanism of moxonidine: role of the inducible nitric oxide synthase in the rostral ventrolateral medulla","volume":"84","author":"Peng","year":"2009","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2012.02.007_bib79","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/cvr\/cvq289","article-title":"GABAergic mechanism in the rostral ventrolateral medulla contributes to the hypotension of moxonidine","volume":"89","author":"Peng","year":"2011","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.cjca.2012.02.007_bib80","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1749-6632.1999.tb09386.x","article-title":"The renal actions of moxonidine are mediated by atrial natriuretic peptide and involve the opioid receptors","volume":"881","author":"Mukaddam-Daher","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cjca.2012.02.007_bib81","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1161\/01.HYP.35.6.1215","article-title":"Atrial natriuretic peptide is involved in renal actions of moxonidine","volume":"35","author":"Mukaddam-Daher","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib82","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.bjp.0706146","article-title":"Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist","volume":"145","author":"El-Ayoubi","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib83","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1161\/01.HYP.30.1.83","article-title":"Clonidine and ST-91 may activate imidazoline-binding sites in the heart to release atrial natriuretic peptide","volume":"30","author":"Mukaddam-Daher","year":"1997","journal-title":"Hypertension"},{"key":"10.1016\/j.cjca.2012.02.007_bib84","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejphar.2006.05.009","article-title":"Receptors involved in moxonidine-stimulated ANP release from isolated hearts of normotensive rats","volume":"541","author":"Mukaddam-Daher","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib85","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1097\/00005344-200206000-00013","article-title":"Imidazoline receptors in the heart","volume":"39","author":"El-Ayoubi","year":"2002","journal-title":"J Cardiovas Pharmacol"},{"key":"10.1016\/j.cjca.2012.02.007_bib86","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1124\/jpet.104.067595","article-title":"Imidazoline receptors but not alpha2-adrenoceptors are regulated in spontaneously hypertensive rat heart by chronic moxonidine treatment","volume":"310","author":"El-Ayoubi","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.cjca.2012.02.007_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1749-6632.1999.tb09335.x","article-title":"Imidazoline receptor antisera-selected cDNA clone and mRNA distribution","volume":"881","author":"Piletz","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cjca.2012.02.007_bib88","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/10445490050043290","article-title":"Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization","volume":"19","author":"Piletz","year":"2000","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.cjca.2012.02.007_bib89","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1083\/jcb.151.6.1141","article-title":"Nischarin, a novel protein that interacts with the integrin alpha5 subunit and inhibits cell migration","volume":"151","author":"Alahari","year":"2000","journal-title":"J Cell Biol"},{"key":"10.1016\/j.cjca.2012.02.007_bib90","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1042\/bj20030411","article-title":"A membrane proximal region of the integrin alpha5 subunit is important for its interaction with nischarin","volume":"377","author":"Alahari","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.cjca.2012.02.007_bib91","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1196\/annals.1304.053","article-title":"Cell signaling by imidazoline-1 receptor candidate, IRAS, and the nischarin homologue","volume":"1009","author":"Piletz","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cjca.2012.02.007_bib92","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1002\/jcb.20806","article-title":"Involvement of phosphatidylcholine-selective phospholipase C in activation of mitogen-activated protein kinase pathways in imidazoline receptor antisera-selected protein","volume":"98","author":"Li","year":"2006","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.cjca.2012.02.007_bib93","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1016\/j.febslet.2006.04.058","article-title":"Nischarin as a functional imidazoline (I1) receptor","volume":"580","author":"Zhang","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.cjca.2012.02.007_bib94","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1471-4159.2006.04413.x","article-title":"Identification of IRAS\/nischarin as an I(1)-imidazoline receptor in PC12 rat pheochromocytoma cells","volume":"101","author":"Sun","year":"2007","journal-title":"J Neurochem"},{"key":"10.1016\/j.cjca.2012.02.007_bib95","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/01.CIR.0000136088.18960.E6","article-title":"Statins inhibit beta-adrenergic receptor-stimulated apoptosis in adult rat ventricular myocytes via a Rac1-dependent mechanism","volume":"110","author":"Ito","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2012.02.007_bib96","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1161\/01.RES.0000204727.46710.5e","article-title":"Regulation of NADPH oxidases: the role of Rac proteins","volume":"98","author":"Hordijk","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2012.02.007_bib97","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1161\/01.RES.0000216039.75913.9e","article-title":"The Rac and Rho Hall of Fame","volume":"98","author":"Brown","year":"2006","journal-title":"Circ Res"},{"key":"10.1016\/j.cjca.2012.02.007_bib98","doi-asserted-by":"crossref","first-page":"3742","DOI":"10.1128\/MCB.01832-07","article-title":"Nischarin inhibits LIM kinase to regulate cofilin phosphorylation and cell invasion","volume":"28","author":"Ding","year":"2008","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.cjca.2012.02.007_bib99","doi-asserted-by":"crossref","first-page":"19439","DOI":"10.1074\/jbc.M111838200","article-title":"Insulin receptor substrate 4 associates with the protein IRAS","volume":"277","author":"Sano","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cjca.2012.02.007_bib100","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1196\/annals.1304.054","article-title":"IRAS is an anti-apoptotic protein","volume":"1009","author":"Dontenwill","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.cjca.2012.02.007_bib101","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1038\/sj.cdd.4401447","article-title":"I1-imidazoline receptor-mediated effects on apoptotic processes in PC12 cells","volume":"11","author":"Dupuy","year":"2004","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.cjca.2012.02.007_bib102","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0891-5849(02)01041-9","article-title":"Protective effects of rilmenidine and AGN 192403 on oxidative cytotoxicity and mitochondrial inhibitor-induced cytotoxicity in astrocytes","volume":"33","author":"Choi","year":"2002","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.cjca.2012.02.007_bib103","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/00207450902787165","article-title":"Protection in glutamate-induced neurotoxicity by imidazoline receptor agonist moxonidine","volume":"119","author":"Bakuridze","year":"2009","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.cjca.2012.02.007_bib104","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/jnci\/djr350","article-title":"Molecular characterization of the tumor-suppressive function of nischarin in breast cancer","volume":"103","author":"Baranwal","year":"2011","journal-title":"J Natl Cancer Inst"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12000967?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X12000967?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:35:49Z","timestamp":1760106949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X12000967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":104,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0828282X12000967"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2012.02.007","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An \u201cI\u201d on Cardiac Hypertrophic Remodelling: Imidazoline Receptors and Heart Disease","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2012.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}